Trial Profile
REgorafenib's Liquid BiopsY (RELY): A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms RELY
- 15 Mar 2021 Status changed from recruiting to completed.
- 30 Dec 2014 New trial record